Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (Part II) Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

NCT03558152
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Greenville, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 26, 2026, 8:14 AM EDT
Completed Phase 1Phase 2 Interventional

YSPSL for Prevention of Delayed Graft Function Part B

NCT00298168
View directory record Official record
Conditions
Kidney Diseases
Interventions
YSPSL, placebo
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Sep 26, 2026, 8:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Assess Safety and Efficacy of VAD044 in HHT Patients

NCT05406362
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
VAD044 Part I, VAD044 Part II
Drug
Lead sponsor
Vaderis Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 26, 2026, 8:14 AM EDT
Completed Phase 1 Interventional

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

NCT02544880
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo
Drug · Biological · Other
Lead sponsor
Donald T. Weed, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 26, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

NCT00035555
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions
Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 26, 2026, 8:14 AM EDT
Completed Phase 1Phase 2 Interventional

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

NCT05440643
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut SLIT-tablet, Placebo
Biological · Other
Lead sponsor
ALK-Abelló A/S
Industry
Eligibility
4 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 26, 2026, 8:14 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows

NCT00752050
View directory record Official record
Conditions
Glabellar Rhytides, Frown Lines Between the Eyebrows
Interventions
Mentor Purified Toxin Botulinum Toxin Type A, Preservative-free Saline
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2011 · Synced Sep 26, 2026, 8:14 AM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

NCT00911963
View directory record Official record
Conditions
Hepatitis C
Interventions
VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 26, 2026, 8:14 AM EDT
Recruiting Phase 2 Interventional

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
5% TolaSure Topical Gel, Topical Placebo Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 26, 2026, 8:14 AM EDT
Enrolling by invitation Not applicable Interventional

Wireless Nerve Stimulation Device To Enhance Recovery After Stroke

NCT04534556
View directory record Official record
Conditions
Stroke, Chronic Stroke, Upper Extremity Paresis, Ischemic Stroke, Hemorrhagic Stroke
Interventions
Active Vagus Nerve Stimulation, Placebo Vagus Nerve Stimulation
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
22 Years to 79 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 26, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

NCT02877134
View directory record Official record
Conditions
Crohn Disease
Interventions
JNJ-64304500, Placebo, Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
37
States / cities
Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 26, 2026, 8:14 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers

NCT05367661
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CHK336, Placebo
Drug
Lead sponsor
Chinook Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 26, 2026, 8:14 AM EDT
Terminated Phase 2 Interventional Results available

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

NCT02087241
View directory record Official record
Conditions
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Interventions
AZD1775, AZD1775 Matching Placebo, pemetrexed, carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Englewood, Colorado • Fort Myers, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 26, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

NCT02700919
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BCT197, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
40 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Michigan City, Indiana • Baltimore, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2020 · Synced Sep 26, 2026, 8:14 AM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

NCT00070122
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
oxaliplatin, leucovorin calcium, capecitabine, bevacizumab, fluorouracil, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 26, 2026, 8:14 AM EDT
Recruiting Phase 2Phase 3 Interventional

An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

NCT03094429
View directory record Official record
Conditions
Refractory Schizophrenia
Interventions
NaBen®, Placebo
Drug · Other
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
18 Years to 55 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 26, 2026, 8:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA

NCT04589611
View directory record Official record
Conditions
Osteoarthritis, Post-traumatic Osteoarthritis
Interventions
amobarbital/Gel-One (one dose), Placebo (single dose), amobarbital/Gel-One (two doses), Placebo (two doses)
Drug
Lead sponsor
J L Marsh
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 26, 2026, 8:14 AM EDT
Terminated Phase 3 Interventional

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

NCT04684511
View directory record Official record
Conditions
Hemophilic Arthropathy
Interventions
TRM-201 (Rofecoxib), Placebo
Drug
Lead sponsor
Tremeau Pharmceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 26, 2026, 8:14 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

NCT00962832
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, Rontalizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
49
States / cities
Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Sep 26, 2026, 8:14 AM EDT
Recruiting Phase 2 Interventional

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

NCT05695261
View directory record Official record
Conditions
Allergy, Peanut, Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Food Allergy, Food Allergy Peanut
Interventions
Microbial Transplantation Therapy, Antibiotic, Placebo (in place of MTT), Placebo (in place of antibiotics), Oral Immunotherapy (OIT)
Biological · Drug · Other
Lead sponsor
Rima Rachid
Other
Eligibility
12 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 26, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

NCT04521114
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Placebo, leronlimab 700 mg, leronlimab 350 mg
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Coronado, California • Maitland, Florida • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 26, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

NCT01821833
View directory record Official record
Conditions
Breast Cancer, Ovarian Neoplasm, Pain
Interventions
Omega-3 fatty acid, Placebo, Paclitaxel
Dietary Supplement · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 26, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

NCT05162586
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 26, 2026, 8:14 AM EDT
Recruiting Phase 2 Interventional

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

NCT05726292
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 26, 2026, 8:14 AM EDT